Search results
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks via Yahoo Finance· 6 days agoMerck MRK boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 5 days agoOne of the drugs, the lung cancer treatment Tagrisso, has already exceeded $5 billion in annual...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 3 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 2 days agoKeytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract...
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
Barrons.com· 2 days agoThe American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual...
Immunotherapy for stomach cancer: Types and effectiveness
Medical News Today· 4 days agoImmunotherapy may help shrink a tumor or slow the growth of cancer cells. People may have it in...
Why This Top 4% Biotech Just Catapulted To A Record High
Investor's Business Daily· 2 days agoThe Netherlands-based biotech paired its drug, petosemtamab, with Merck's (MRK) cancer blockbuster, ...
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Zacks· 3 days agoFree Report) announced updated clinical results from a cohort of the phase II IOV-COM-202 study evaluating the combination of its recently approved cell therapy Amtagvi and Merck’s blockbuster ...
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 3 days agoEisai announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology ...
Merus Shares Surge 36% On Early Data of Potential Head, Neck Cancer Treatment
Market Watch· 2 days agoShares of Merus surged higher Friday after the company's head and neck cancer treatment candidate showed a reduction in the disease in 60% of evaluable patients in an early ...